# Convergent Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/convergent-therapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.convergentrx.com
- Total disclosed funding: $29M
- Latest round: Series A (Apr 27, 2023)
- Investors on record: 3

## About

Founded in 2021 and based in Massachusetts, US, Convergent Therapeutics, Inc. is a company that focuses on developing solutions for treating cancer. Philip Kantoff (CEO/CMO) and Neil Bander are the co-founders of the company. In September 2024, Convergent Therapeutics, Inc. raised USD 40 million in series A funding from new investor Novo Holdings.

The company's product candidate is CONV01-a, a radioantibody that is specifically directed against PSMA, an antigen that is expressed on the surface of almost all prostate cancer cells. Treatment techniques like chemotherapy, hormone therapy, surgery, targeted therapy, radiation therapy, and immunotherapy can all benefit from CONV01-a.

The firm leverages radioantibody technology to target and destroy cancer cells with the least amount of harm to healthy tissues. To create radioantibodies, Convergent Therapeutics' patented antibodies are combined with radionuclides like actinium-225 (225Ac). These radioantibodies attach to receptors on the surface of cancer cells and are then taken up by the tumor cells internally. After entering, they carry their radioactive payload directly to the cell's nucleus, where it causes permanent DNA damage and cell death.

The organization plans to use the September 2024 funding to support the development of its radiopharmaceuticals.

## Funding rounds

- Series A, Apr 27, 2023, $29M — OrbiMed Advisors, Invus [DUP], RA Capital Management

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A
- Invus [DUP] — Series A
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series A